Invitrogen Launches Vector NTI Advance 10
Release Includes Vector NTI Open Access Policy and Vector NTI User Community to Drive Life Science Standardization
Carlsbad, CA - Invitrogen Corporation, a life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, announced the release of its latest technology and eScience contribution to the life sciences, Vector NTI Advance 10. Centering on its award-winning Vector NTI sequence analysis software, Vector NTI Advance 10 is the latest Windows version of this application.
To coincide with the release, Invitrogen is also launching the Vector NTI Open Access policy and the online Vector NTI User Community. The Open Access policy allows researchers in not-for-profit laboratories to obtain their own annual, renewable licenses of Vector NTI® at no cost. The Vector NTI® User Community is designed to be the online meeting place for researchers to acquire the latest versions of the software, obtain technical resources, and ultimately communicate with Invitrogen and other users on all aspects of the software and its uses.
"The launch of Vector NTI Advance 10 and the creation of a Vector NTI® Open Access policy continues our commitment to making our technologies more powerful and more accessible to researchers in all areas of life science," said Gregory T. Lucier, Chairman and CEO of Invitrogen. "We recognize the need researchers have for access to the best possible tools to drive research forward. We also believe in the importance of having standards in the life sciences industry, and Vector NTI software is capable of performing that role. We look forward to having tens of thousands of users in the academic, government and research institutions take advantage of our Open Access policy."
Two major research institutions have reviewed the Open Access policy and have utilized Vector NTI software across their campuses. The Wellcome Trust Sanger Institute, a world-renowned genome center best known for its major contributions to the Human Genome Project, understands the importance of researchers having access to state-of-the art bioinformatics tools, as well as the need for standard applications and analyses. All the basic sequence data and all software tools developed at the Institute are released freely into the public domain.
"We use a wide range of different software for different informatics needs and Vector NTI is a very powerful suite of DNA and protein sequence analysis tools," said Dr. Gareth Maslen, Informatics Project Manager at the Sanger Institute. "The Open Access Policy allows us to receive free, annual licenses for our Vector NTI software, and we envisage this will simplify deployment of the software and improve access for our researchers."
Invitrogen has also been working with The Scripps Research Institute. Vector NTI desktop software is now available to all researchers at the Scripps Florida campus.
"We appreciate the Open Access policy because The Scripps Research Institute is committed to supporting efforts that provide greater access to the tools and data that are crucial to helping life science researchers understand biology," says Dr. Nick Tsinoremas, Director of Informatics at Scripps Florida. "The benefits to the scientific community of Invitrogen's drive for standardization are clear, not only can students and post-docs conduct their research using the latest software, but they are also better prepared for the academic, pharmaceutical and biotechnology jobs of tomorrow. The fact that Vector NTI® software imports, handles and exports data in all the key public sequence file formats means that sharing data among groups of researchers is easier than ever."
SOURCE: Invitrogen Corporation